LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
https://doi.org/10.15829/1560-4071-2018-4-89-92
Abstract
The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).
About the Author
S. V. Nedogoda
Volgograd State Medical University of the Ministry of Health.
Russian Federation
Volgograd.
Russian Federation
Volgograd.
References
1. Sattar N, Petrie MC, Zinman B, et al. Novel diabetes drugs and the cardiovascular specialist. Journal of the American College of Cardiology. 2017 May 22; 69 (21): 2646-56. DOI: 10.1016/j.jacc.2017.04.014.
2. www.siditalia.it/news/1229-26-07-2016-position-statement-sid-farmaciipoglicemizzanti-malattie-cardiovascolari-e-renali.
3. Lehmann R, Bianda T, Brändle M, et al. Arbeitsgruppe der SGED/SSED Empfehlungen der SGED/SSED: Massnahmen zur Blutzuckerkontrolle bei Patien-ten mit Diabetes mellitus Type 2. http://sgedssed.ch/fileadmin/files/6_empfehlungen_fachpersonen/61_richtlinien_fachaerzte/SGED_Empfehlung_BZ-Kontrolle_T2DM_Finale_Version_12_korr_17.10.16.pdf.
4. Nasjonal faglig retningslinje for diabetes. Nasjonal faglig retningslinje for diabetes Sist oppdatert 20.9.2016. https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=8&ved=0ahUKEwiFjdXg7IjVAhUoDZoKHRKCAR8QFghVMAc&url=https%3A%2F%2Fmitt.uib.no%2Fcourses%2F1966%2Ffiles%2F213291%2Fdownload%3Fdownload_frd%3D1&usg=AFQjCNGKGkmUfeZtHrmv41XGmwYnNk7VBw&cad=rjt.
5. Policies, Guidelines, and Consensus Statements Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2016; 40: 484-6.
6. Landgraf R, Kellerer M, Fach E, et al. Praxisempfehlungen DDG/DGIM. Diabetologie und Stoffwechsel. 2016 Oct;11 (S 02): S117-29.
7. Clinical guidelines. Algorithms of specialized medical care to patients with diabetes. Ed. Dedova II, Shestakova MV, Mayorova A. Yu. Diabetes mellitus 2017; 20 (1S): 1-112. (In Russ.) Клинические рекомендации “Алгоритмы специализированной медицинской помощи больным сахарным диабетом”, под ред. Дедова И. И., Шестаковой М. В., Майорова А. Ю. Сахарный диабет 2017; 20 (1S): 1-112. DOI: 10.14341/DM20171S8.
8. Editorial a. The possibility of reducing cardiovascular risk in patients with diabetes mellitus type 2. Russian Journal of Cardiology. 2017; 9: 99-103. (In Russ.) Редакционная с. Возможности снижения сердечно-сосудистых рисков у пациентов с сахарным диабетом 2 типа. Российский кардиологический журнал. 2017; 9: 99-103. DOI: 10.15829/1560-4071-2017-9-99-103.
9. www.who.int
10. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
11. Neaton JD, Wentworth DN, Cutler J, et al. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Research Group. Ann Epidemiol 1993; 3: 493-9.
12. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010 Jun 26; 375 (9733): 2215-22.
13. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.
14. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
15. Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. N Engl J Med 1998; 339: 229-34.
16. Rydén L, Grant P, Anker S, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russian Journal of Cardiology. 2014; 3 (107): 7-61. (In Russ.) Rydén L, Grant P, Anker S, et al. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ESC. Рабочая группа по диабету, предиабету и сердечно-сосудистым заболеваниям Европейского общества кардиологов (ESC) в сотрудничестве с Европейской ассоциацией по изучению диабета (EASD). Российский кардиологический журнал 2014, 3 (107): 7-61.
17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med 2016; 375: 311-22. DOI: 10.1056/NEJMoa1603827.
18. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.
19. Ettehad D, Emdin CA, Kiran A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet 387.10022 (2016): 957-67. DOI: 10.1016/S0140-6736(15)01225-8.
20. Higgins M, Kannel W, Garrison R, et al. Hazards of Obesity-the Framingham Experience. Journal of Internal Medicine. 1987 Jan 12; 222 (S723): 23-36.
21. Bouchi R, Nakano Y, Fukuda T, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocrine journal. 2017; 64 (3): 269-81.
22. Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Medicine. 2008 Sep 1; 25 (9): 1129-31.
23. Díaz-Soto G, de Luis DA, Conde-Vicente R, et al. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: a prospective study. Diabetes research and clinical practice. 2014 Apr 1; 104 (1): 92-6.
24. Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013 Oct 1; 36 (10): 3276-82.
25. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell metabolism. 2016 Jul 12; 24 (1): 15-30.
26. Thorens B, Porret A, Bühler L, et al. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes. 1993 Nov 1; 42 (11): 1678-82.
27. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999 Jan 1; 44 (1): 81-6.
28. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology & Metabolism. 1995 Mar 1; 80 (3): 952-7.
29. Hansen L, Deacon CF, Ørskov C, et al. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999 Nov 1; 140 (11): 5356-63.
30. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry. 1992 Apr 15; 267 (11): 7402-5.
31. Falko JM, Crockett SE, Cataland S, et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. The Journal of Clinical Endocrinology & Metabolism. 1975 Aug 1; 41 (2): 260-5.
32. McIntyre NE, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. The Journal of Clinical Endocrinology & Metabolism. 1965 Oct 1; 25 (10): 1317-24.
33. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016; 18: 203-16.
34. Du Q, Wang YJ, Yang S, et al. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 2014; 31: 1182-95.
35. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3.
36. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care 2016; 39 (2): 222-30.
37. Zavattaro M, Caputo M, et al. One-year treatment with liraglutide improved renal functionin patients with type 2 diabetes: a pilot prospective study. Endocrine 2015; 50 (3): 620-6.
38. American Diabetes Association Standards of Medical Care in Diabetes, 2017. Diabetes Care 2017; 40 (Suppl 1): 1-142. 1-142
Review
For citations:
Nedogoda S.V. LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST. Russian Journal of Cardiology. 2018;(4):89-92. (In Russ.) https://doi.org/10.15829/1560-4071-2018-4-89-92
Views:
1027
Email this article 